Oral supplementation with L-glutamine alters gut microbiota of obese and overweight adults: A pilot study

Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI) study: study protocol for a randomized controlled trial

Background

Early reperfusion of the occluded coronary artery during acute myocardial infarction is considered crucial for reduction of infarcted mass and recovery of ventricular function. Effective microcirculation and the balance between protective and harmful lymphocytes may have roles in reperfusion injury and may affect final ventricular remodeling.

Methods/design

BATTLE-AMI is an open-label, randomized trial comparing the effects of four therapeutic strategies (rosuvastatin/ticagrelor, rosuvastatin/clopidogrel, simvastatin plus ezetimibe/ticagrelor, or simvastatin plus ezetimibe/clopidogrel) on infarcted mass and left ventricular ejection fraction (LVEF) (blinded endpoints) in patients with ST-segment elevation myocardial infarction submitted to fibrinolytic therapy before coronary angiogram (pharmacoinvasive strategy). All patients (n = 300, 75 per arm) will be followed up for six months. The effects of treatment on subsets of B and T lymphocytes will be determined by flow-cytometry/ELISPOT and will be correlated with the infarcted mass, LVEF, and microcirculation perfusion obtained by cardiac magnetic resonance imaging. The primary hypothesis is that the combined rosuvastatin/ticagrelor therapy will be superior to other therapies (particularly for the comparison with simvastatin plus ezetimibe/clopidogrel) for the achievement of better LVEF at 30 days (primary endpoint) and smaller infarcted mass (secondary endpoint) at 30 days and six months. The trial will also evaluate the improvement in the immune/inflammatory responses mediated by B and T lymphocytes. Omics field (metabolomics and proteomics) will help to understand these responses by molecular events.

Discussion

BATTLE-AMI is aimed to (1) evaluate the role of subsets of lymphocytes on microcirculation improvement and (2) show how the choice of statin/antiplatelet therapy may affect cardiac remodeling after acute myocardial infarction with ST elevation.

Trial registration

ClinicalTrials.gov, NCT02428374. Registered on 28 September 2014.

Electronic supplementary material

The online version of this article (doi:10.1186/s13063-017-2361-1) contains supplementary material, which is available to authorized users.

Relationships between gut microbiota, plasma metabolites, and metabolic syndrome traits in the METSIM cohort

BACKGROUND

The gut microbiome is a complex and metabolically active community that directly influences host phenotypes. In this study, we profile gut microbiota using 16S rRNA gene sequencing in 531 well-phenotyped Finnish men from the Metabolic Syndrome In Men (METSIM) study.

RESULTS

We investigate gut microbiota relationships with a variety of factors that have an impact on the development of metabolic and cardiovascular traits. We identify novel associations between gut microbiota and fasting serum levels of a number of metabolites, including fatty acids, amino acids, lipids, and glucose. In particular, we detect associations with fasting plasma trimethylamine N-oxide (TMAO) levels, a gut microbiota-dependent metabolite associated with coronary artery disease and stroke. We further investigate the gut microbiota composition and microbiota-metabolite relationships in subjects with different body mass index and individuals with normal or altered oral glucose tolerance. Finally, we perform microbiota co-occurrence network analysis, which shows that certain metabolites strongly correlate with microbial community structure and that some of these correlations are specific for the pre-diabetic state.

CONCLUSIONS

Our study identifies novel relationships between the composition of the gut microbiota and circulating metabolites and provides a resource for future studies to understand host-gut microbiota relationships.

Glutamine and the regulation of intestinal permeability: from bench to bedside

PURPOSE OF REVIEW

Glutamine is the most abundant amino acid in plasma and plays a key role in maintaining the integrity of intestinal barrier.

RECENT FINDINGS

Experimental studies showed that glutamine is able to modulate intestinal permeability and tight junction protein expression in several conditions. Recent articles underlined its putative beneficial role in gastrointestinal disorders such as irritable bowel syndrome.

SUMMARY

Glutamine is a major nutrient to maintain intestinal barrier function in animals and humans. Depletion of glutamine results in villus atrophy, decreased expression of tight junction proteins and increased intestinal permeability. Moreover, glutamine supplementation can improve gut barrier function in several experimental conditions of injury and in some clinical situations. Furthermore, preventive effects of glutamine in experimental models of intestinal injuries have been recently reported. Despite promising data in experimental models, further studies are needed to evaluate glutamine supplementation in clinical practice.

Mucosal Interactions between Genetics, Diet, and Microbiome in Inflammatory Bowel Disease

Numerous reviews have discussed gut microbiota composition changes during inflammatory bowel diseases (IBD), particularly Crohn’s disease (CD). However, most studies address the observed effects by focusing on studying the univariate connection between disease and dietary-induced alterations to gut microbiota composition. The possibility that these effects may reflect a number of other interconnected (i.e., pantropic) mechanisms, activated in parallel, particularly concerning various bacterial metabolites, is in the process of being elucidated. Progress seems, however, hampered by various difficult-to-study factors interacting at the mucosal level. Here, we highlight some of such factors that merit consideration, namely: (1) the contribution of host genetics and diet in altering gut microbiome, and in turn, the crosstalk among secondary metabolic pathways; (2) the interdependence between the amount of dietary fat, the fatty acid composition, the effects of timing and route of administration on gut microbiota community, and the impact of microbiota-derived fatty acids; (3) the effect of diet on bile acid composition, and the modulator role of bile acids on the gut microbiota; (4) the impact of endogenous and exogenous intestinal micronutrients and metabolites; and (5) the need to consider food associated toxins and chemicals, which can introduce confounding immune modulating elements (e.g., antioxidant and phytochemicals in oils and proteins). These concepts, which are not mutually exclusive, are herein illustrated paying special emphasis on physiologically inter-related processes.

Optimization of medium composition for in vitro shoot proliferation and growth of date palm cv. Mejhoul

The effects of major mineral salts, l-glutamine, myo-inositol and carbon source on shoot bud proliferation of date palm (Phoenix dactylifera L.) cv. Mejhoul were evaluated. Different concentrations of ammonium nitrate (NH₄NO₃; 550, 825 or 1650 mg/L), potassium nitrate (KNO₃; 633.3, 950 or 1900 mg/L), calcium chloride dehydrate (CaCl₂·2H₂O; 147, 220 or 440 mg/L), potassium dihydrogen phosphate (KH₂PO₄; 57, 85 or 170 mg/L), magnesium sulfate heptahydrate (MgSO₄·7H₂O; 123, 185 or 370 mg/L), l-glutamine and myo-inositol (0.5, 1, 1.5 and 2 g/L), sucrose, sorbitol, mannitol or commercial granulated sugar (10, 20, 30, 40 or 50 g/L) were tested. The highest number of shoot buds per explant (18.7) occurred on the medium containing 825 mg/L NH₄NO₃, 1900 mg/L KNO₃, 220 mg/L CaCl₂·2H₂O, 170 mg/L KH₂PO₄, 370 mg/L MgSO₄·7H₂O as well as 1 g/L l-glutamine, 2 g/L myo-inositol and 30 g/L sucrose. The results showed that the frequency of hyperhydricity significantly increased in media containing 1650 mg/L NH₄NO₃. The concentrations of l-glutamine, myo-inositol and carbon source significantly affected the number of shoot buds per explant. However, they had no effect on hyperhydricity, tissue browning and precocious rooting. Shoots of 4.5–6.0 cm in length were isolated and transferred onto hormone-free media for elongation and rooting. After 3 months, the developed plantlets were successfully transplanted in a glasshouse and over 90 % survived acclimatization.

Glutamine promotes intestinal SIgA secretion through intestinal microbiota and IL-13

SCOPE

Glutamine supplementation enhances secretory IgA (SIgA) production in the intestine, but the mechanism is largely unknown. We examined this issue using a mouse model.

METHODS AND RESULTS

In mouse model, glutamine supplementation increased both SIgA abundance in intestinal luminal contents and IgA(+) plasma cell numbers in the mouse ileum, and decreased bacterial loads in mouse mesenteric lymph nodes. Glutamine supplementation increased mouse ileal expression of cytokines associated with T cell-dependent and T cell-independent pathways of SIgA induction, including IL-5, IL-6, IL-13, transforming growth factor (TGF-β), a proliferation-inducing ligand (APRIL), B cell-activating factor (BAFF), vasoactive intestinal peptide (VIP) receptor, and retinal dehydrogenases. Injecting an IL-13 antibody during glutamine supplementation reduced J-chain expression in the mouse ileum. Glutamine supplementation increased bacterial invasion into the mouse ileal wall, while disrupting the mouse intestinal microbiota abrogated the influence of glutamine supplementation on SIgA secretion.

CONCLUSION

Glutamine supplementation appears to enhance SIgA secretion in the mouse intestine through the intestinal microbiota and subsequently through T cell-dependent and T cell-independent pathways.

Modulation of gut microbiota in rats fed high-fat diets by processing whole-grain barley to barley malt

SCOPE

The gut microbiota is linked with human health, and by manipulating its composition, health conditions might be improved. The aim of this study was to investigate whether two barley products, whole-grain barley and barley malt, caused differentiation of the cecal microbiota in rats fed high-fat diets and whether there were correlations with the short-chain fatty acids formed.

METHODS AND RESULTS

Male Wistar rats were given barley or malt (7-8 dietary fiber/100 g) for 4 weeks. Cellulose was used as a control, and the cecal microbiota was analyzed with next-generation sequencing of 16S rDNA. The barley group had higher abundances of Verrucomicrobia and Actinobacteria and lower abundances of Firmicutes and Deferribacteres than the control group; the alpha diversity was also lower. At the genus level, the barley group had higher abundances of Akkermansia, Ruminococcus, Blautia, and Bilophila. Turicibacter and Roseburia were more abundant in the malt group, and Parabacteroides, Dorea and rc4-4 were enriched in the control group. Most genera correlated with acetic and propionic acids, but Roseburia and Turicibacter instead correlated with butyric acid. Succinic acid correlated with Clostridium and Akkermansia.

CONCLUSION

Bioprocessing is a potential method to modulate the gut microbiota for enhanced effects on human health.